Replies to post #417821 on ORIONS Money Stocks

[crudeoil24]

SNSS > CONFIDENTIAL TREATMENT filing with SEC, March 18, 2019. Targeting a mechanism of resistance to first-generation BTK inhibitors caught the attention of biotechs, which is claiming major success this month. Big pharma also involved. Bank of America and Merrill Lynch, BTK inhibitor market potential is huge, ~$16B

[Mark]

$SNSS 1.28 in A/Hs, been pounding the table since high .50s a few weeks back....

Mark
Thursday, 03/07/19 10:23:23 AM
Re: None
0
Post # of 417823

$SNSS .58 breaking out, this can see $1+ easy imo, has shorts